The analyst rating for MANULIFE-S (00945.HK) was elevated to "Buy" by DBS Group Research due to several key factors. The report highlights the company's growth-centric innovative strategies, which include strong growth potential in Asia and global wealth and asset management businesses, as well as investment expansion in Canada and the US to maintain a diversified portfolio. Additionally, the transformation into an AI-powered institution and enhancements in client health, wealth, and longevity protection through value-added solutions are seen as positive developments.
DBS Group Research believes these strategic focuses will help MANULIFE achieve its 2027 financial targets and strengthen its long-term growth trajectory. Consequently, the target price was raised from $290 to $310. However, the report also cautions investors about potential risks, such as significant drops in interest rates, rising equity market volatility, and slower-than-expected growth in Asian markets.
